Statistics and data science

The MedTech and BioTech sectors in the Netherlands are highly innovative but operate under significant pressure due to complex regulations and limited resources. Companies must make early-stage decisions that strongly influence clinical validation, regulatory approval, and scaling. As a result, organizations frequently face critical questions about statistical justification, data quality for regulators, clinical study design, and risk management—especially at key decision points that impact timelines, budgets, and market entry.

CQM supports these organizations as a hands-on partner by providing expertise in statistics, biostatistics, and data science throughout development and validation. Their support spans embedded analytics, clinical validation, and product development, ensuring solutions are both technically sound and regulator-ready. A strong data-driven approach helps companies reduce risks, avoid delays, accelerate progress, and build confidence with regulators and investors, ultimately improving the chances of successful market introduction.